The Semaglutide Revolution Market Study

Few pharmaceuticals have changed the world like glucagonlike peptide-1 (GLP-1) agonists. Originally approved and marketed as tools to lower blood sugar in diabetics, the publication and promotion of off-label weight loss capabilities of brands including Ozempic, Wegovy, Rybelsus (semaglutide), Victoza (Liraglutide), and Zepbound and Mounjaro (Tirzepatide), led to worldwide shortages for diabetic patients — and billions of dollars in sales for key makers Eli Lilly and Novo Nordisk.